20 July 2021
The revised general chapter 5.21 has been published in Pharmeuropa 33.3, the European Pharmacopoeia online forum, for public comment.
The revised general chapter Chemometric methods applied to analytical data (5.21) has been published in this quarter’s issue of Pharmeuropa (33.3), the European Pharmacopoeia (Ph. Eur.) online forum for public comment.
The chapter is an introduction to the use of chemometrics and data science techniques. Chemometrics is the application of mathematical and statistical techniques to yield chemical information from complex data. It is particularly important in the pharmaceutical industry as it transforms data in order to allow for chemical interpretations that are not evident from the raw statistics, usually achieved by applying a number of powerful multivariate analytical techniques (MVA) to develop a model to predict or quantify the property of interest for new samples or process runs. The objective of this chapter was to provide indications on good practice and requirements for the processing of analytical data.
The general chapter was first published in 2015 (Supplement 8.7), however its revision was prompted by the continuous evolution in data science techniques since the date of publication. Pharmeuropa acknowledged that data analysis is an extremely dynamic field which has led to numerous changes in the way algorithms are referenced and applied.
In light of the latest developments, Pharmeuropa have completely rewritten or updated numerous sections of the chapter and new sections/sub-sections have been introduced. The general revision includes:
The deadline for comments is 30 September 2021. Comments from within the member states should be sent to the responsible national pharmacopoeial authority, while comments from countries outside the Ph. Eur. Convention or from industry associations can be sent to the European Directorate for the Quality of Medicines & HealthCare (EDQM).
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024